IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 670
NA - Nord America 398
EU - Europa 223
OC - Oceania 11
SA - Sud America 7
AF - Africa 4
Totale 1.313
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 446
US - Stati Uniti d'America 387
HK - Hong Kong 105
CN - Cina 79
GB - Regno Unito 70
DE - Germania 36
CZ - Repubblica Ceca 34
IT - Italia 33
IN - India 16
NL - Olanda 14
AU - Australia 11
CA - Canada 9
BE - Belgio 6
FI - Finlandia 6
BR - Brasile 5
JP - Giappone 5
UA - Ucraina 5
FR - Francia 4
TW - Taiwan 4
ZA - Sudafrica 4
ID - Indonesia 3
PT - Portogallo 3
TR - Turchia 3
AL - Albania 2
CL - Cile 2
EE - Estonia 2
IE - Irlanda 2
PK - Pakistan 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
BD - Bangladesh 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ES - Italia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
YE - Yemen 1
Totale 1.313
Salva come PNG Salva come JPEG
Città #
Singapore 161
Hong Kong 103
Ashburn 102
Boardman 93
London 67
Shanghai 47
Brno 23
Rome 23
Redmond 21
Los Angeles 20
San Francisco 20
Council Bluffs 15
Amsterdam 14
Pune 13
Munich 10
Olomouc 10
Santa Clara 9
Seattle 9
Toronto 7
Washington 7
Helsinki 6
Melbourne 5
Shenzhen 4
Tokyo 4
Canberra 3
Guangzhou 3
Haikou 3
Mol 3
Sydney 3
São Paulo 3
Taipei 3
Aversa 2
Dublin 2
Genoa 2
Hanover 2
Hasselt 2
Lodz 2
New Delhi 2
North Liberty 2
Oklahoma City 2
Paris 2
Porto 2
Tallinn 2
Tirana 2
West Jordan 2
Almaty 1
Berlin 1
Brussels 1
Central District 1
Centurion 1
Charlotte 1
Chicago 1
Chongqing 1
Clifton 1
Colombo 1
Columbia 1
Dhaka 1
Frankfurt am Main 1
Guiyang 1
Hangzhou 1
Hefei 1
Hicksville 1
Kunming 1
Lisbon 1
Ma'anshan 1
Manila 1
Mexico City 1
Minsk 1
Naples 1
Quilpué 1
Riyadh 1
Rockville 1
Saint-Cyr-sur-Loire 1
Sanaa 1
Sona 1
Swansea 1
Wuhan 1
Xingtai 1
Totale 875
Salva come PNG Salva come JPEG
Nome #
Anthracycline Cardiotoxicity 37
What is cardiotoxicity? 35
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 34
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 31
Anthracyclines 30
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 26
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 26
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 25
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 24
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 24
Anthracycline Cardiotoxicity 24
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 23
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 23
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 23
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 23
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 23
Pharmacology of Cardio-Oncology 23
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 23
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 22
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 22
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 21
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 21
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 21
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 21
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 20
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 20
Cardiotoxicity of antitumor drugs 20
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 20
Cancer drugs and QT prolongation: weighing risk against benefit 19
Isavuconazole: case report and pharmacokinetic considerations 19
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 19
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 19
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 19
Matters of the heart: The case of TNF-alpha targeting drugs 18
The concomitant management of cancer therapy and cardiac therapy 18
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 18
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 17
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 17
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 16
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 16
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 16
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 16
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 16
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 16
Minimal sampling colistin pharmacokinetics in critically ill patients 16
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 15
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 15
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 15
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 15
Doxorubicin degradation in cardiomyocytes 14
Pharmacological Foundation of Cardio-Oncology 14
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 14
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 14
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 13
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 13
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 13
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 13
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 13
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 12
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 12
Translating molecular mechanisms into clinical facts 12
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 12
Molecular determinants of the reduced cardiotoxicity of epirubicin 12
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 12
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 11
Do you know pixantrone? 11
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 11
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 11
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 11
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 11
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 11
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 10
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 10
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 10
The reality of pixantrone in real life 9
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 9
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 9
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 9
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 8
Humans and Rodents: The Case of hOAT4 and mOat5 7
Totale 1.391
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.962
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.962
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 4 0 0 0 0 1 73 3 0 4 101
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024280 5 32 8 12 32 123 4 16 2 7 4 35
2024/2025879 74 34 107 13 42 68 37 20 222 238 24 0
Totale 1.391